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Summary
Aim. We report our experience on the manage-
ment of Hurthle cell neoplasms (HCNs) of the
thyroid and a review of the literature in order to
describe the most relevant clinical, diagnostic,
biologic and therapeutic aspects. Materials and
Methods.We retrospectively reviewed the clinical
records of 15 consecutive patients with HCN. The
male/female ratio was 1:4 and the mean age was
53.8 years. Fourteen patients underwent total
thyroidectomy and one patient lobectomy. Two
patients were lost to follow up. The mean follow
up time was 54 months. Results. Eleven Hurthle
cell adenomas and 4 carcinomas were found. At
the time of initial surgical evaluation 9 patients
(60%) were symptomatic, with hyperthyroidism
and dysphagia being the most frequent manifesta-
tions. Only in 6 (40%) cases the diagnosis was
obtained by preoperative fine needle aspiration
biopsy. Among patients with Hurthle cell
adenoma and carcinoma the mean age was 51 and
62 years respectively and the mean lesion size 1.6
Riassunto
Obiettivo. Riportiamo in questo articolo la nostra
esperienza nel management delle neoplasie a cel-
lule di Hurthle (HCNs) ed una revisione della let-
teratura allo scopo di sottolineare i più importan-
ti aspetti clinici, diagnostici, biologici e terapeuti-
ci. Materiali e metodi. Abbiamo esaminato i dati
clinici di 15 pazienti consecutivi con HCN. L’età
media dei pazienti era di 53,8 anni e il rapporto
maschi/femmine 1:4. Quattordici pazienti sono
stati sottoposti a tiroidectomia totale ed uno a lo-
bectomia. Due pazienti sono stati persi al follow
up. Il tempo medio di follow up era di 54 mesi. Ri-
sultati. Undici pazienti sono stati trovati affetti da
adenoma a cellule di Hurthle e 4 da carcinoma.
Nove pazienti (60%) erano sintomatici, e solo in 6
(40%) casi la diagnosi è stata ottenuta tramite
biopsia con ago aspirato. L’età media dei pazien-
ti affetti da adenoma era 51 anni e di quelli con
carcinoma 62. La dimensione media delle lesioni
era superiore nei pazienti con carcinoma (3,8 cm
verso 1,6 in quelli con adenoma). Non sono stati
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Introduction
Hurthle cell neoplasms (HCNs) are rare tumors of
the thyroid gland, composed for more than 75% of
oncocytic or Hurthle cells and may be benign
(adenomas) or malignant (carcinomas). Hurthle cell
carcinomas (HCCs) assess for approximately 3-7% of
well differentiated thyroid carcinomas (1-5). HCNs
are characterized by a broad spectrum of clinical
manifestations and the imaging techniques routinely
employed for clinical assessment present a low speci-
ficity. Fine needle aspiration biopsy (FNAB) is often
able to detect oncocytic cells but it is of limited utility
in identifying eventual capsular or vascular tumoral
invasion. Addictively, several authors sustain that
Hurthle cell adenomas (HCAs) may be potentially
malignant and capable of local or distant spreading.
These features of HCNs may render challenging the
diagnosis and the choice of the appropriate treatment.
In this article we report our experience on the
management of HCNs and a review of the literature
in order to describe the most relevant clinical, diag-
nostic and therapeutic implications.
Materials and methods
In the last 10 years we performed in our institution
640 surgical interventions for thyroid disease.
Fifteen cases of HCNs were retrospectively identi-
fied, accounting for 2.3% of the overall surgical
operations: twelve women and three men
(male/female ratio = 1:4) and mean age 53.8 years
(range 26-76). Fourteen patients (93.3%) were
affected by a single lesion, while one (6.7%)
presented two synchronous HCAs (Table 1).
Preoperative assessment was performed through
neck ultrasound in all cases and no cervical
lymphadenopathy was observed. Computed tomog-
raphy (CT) scan examination was not employed in
this cohort. Eleven patients (73.3%) preoperatively
underwent FNAB. Such procedure was not
performed in four patients with voluminous multin-
odular goiter in whom a HCN was occasionally
discovered at histopathlogical examination of the
surgical specimen.
Fourteen (93.3%) total thyroidectomies (TTs) and
one lobectomy (in a young lady with a small lesion)
were performed by a senior surgeon with standard
open approach, as we reported in the past (6,7).
Three cases of early post-operative hypocalcemia
and one case of recurrent laryngeal nerve damage
were observed. No bleeding or other complications
were seen.
Thirteen out of 15 patients were interviewed by
phone and clinical and survival data were collected,
while two patients with HCA were lost to follow up.
The mean follow up time was 54 months (3 - 120).
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and 3.8 cm respectively. No cases of death or
recurrence were registered. Conclusions. Clinical
manifestations are similar to those for other
differentiated thyroid neoplasms. Patients with
Hurthle cell carcinoma presented a mean age and
a mean tumor size greater than those with
Hurthle cell adenoma. Our data suggest that
adenomas have not a malignant potential; never-
theless surgical resection is necessary to obtain a
precise evaluation of eventual infiltrative events.
Surgical resection is also the treatment of choice
for the treatment of carcinomas with total
thyroidectomy representing the best surgical
option. Eur. J. Oncol., 17 (4), 181-188, 2012
Key words: thyroid, Hurthle cell, oncocytic,
oxyphilic, thyroidectomy
osservati decessi o recidive. Conclusioni. Abbia-
mo osservato una differenza di età e di dimensio-
ne delle lesioni tra i pazienti affetti da adenoma e
quelli affetti da carcinoma. I nostri dati suggeri-
scono che gli adenomi a cellule di Hurthle non
hanno potenziale maligno, tuttavia l’asportazione
chirurgica è necessaria per la valutazione di even-
tuali eventi infiltrativi. Il trattamento chirurgico
con tiroidectomia totale o resezioni più ampie ove
necessario rappresenta il trattamento di scelta
per i carcinomi. Eur. J. Oncol., 17 (4), 181-188,
2012
Parole chiave: tiroide, cellule di Hurthle, oncociti-
co, ossifilico, tiroidectomia
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Results
Table 1 summarizes the principal demographic,
clinical, pathological and prognostic findings.
At the time of initial surgical evaluation 6 patients
(40%) did not refer any symptom while nine (60%)
were symptomatic. The clinical manifestations
observed in the latter patients were: hyperthyroidism
and dysphagia in four cases (26.7%), hypothyroidism
in two cases (13.3%), dyspnea, dysphonia and
hypoparathyroidism in one case (6.7%). Nine
patients (60%) presented a normal functional thyroid
status. The mean time between onset of symptoms
and surgery was 38 months (1 - 204).
In nine (60%) cases the diagnosis of a HCN was
fortuitous, while in six cases (40%) the diagnosis of
a HCN was preoperatively obtained by FNAB. Two
of the nine patients who had a fortuitous diagnosis of
HCN were affected by a HCC, detected after
histopathological examination of the surgical spec-
imen. Totally 11 patients (73.3%) underwent FNAB
and among them six (54.5%) had a HCN diagnosis,
while four (36.4%) had a diagnosis of colloidal
goiter. In one case repeated FNAB resulted non
diagnostic.
Eleven patients (73.3%) were found to be affected
from a HCA and four patients (26.7%) from HCC.
The mean age of patients affected of HCA and HCC
was 51 and 62 years respectively. The mean size of
HCA lesions was 1.6 cm and that of HCCs was 3.8
cm. Eleven patients (73%) were affected by at least
one additional pathological condition: colloidal
goiter in ten cases (multinodular goiter is endemic in
Sardinia), papillary carcinoma in three cases,
chronic thyroiditis in two cases and parathyroid
adenoma in one case. Among patients with HCC
vascular invasion was present in all cases, while
capsular invasion was detected in two cases (50%).
All 13 patients whose telephone number was
available were alive and the long term surgical
183
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Table 1 - Demographic, clinical, pathological and prognostic findings
Patient Age Sex Hormonal FNA Surgery Histology Max Histologically Radioiodine Follow Up
(years) (M - F) State dimension found treatment (state -
(cm) comorbidities months)
1 43 F Hypothyroid No TT HCA 0.5 Goiter No Not available
2 39 F Euthyroid Yes TT HCA 3 Goiter No Alive - 120
3 55 F Hyperthyroid Yes TT HCA 3.5 No No Alive - 113
4 33 F Euthyroid Yes TT HCA 0.8 - 1.2 No No Alive - 108
5 74 F Hyperthyroid Yes TT HCC 1.2 No Yes Alive - 101
6 43 M Euthyroid Yes TT HCC 4 Goiter Yes Alive - 66
7 50 F Hyperthyroid Yes TT HCA 0.6 No No Alive - 48
8 76 F Euthyroid Yes TT HCA 2.5 Papillary cancer + Yes Not available
Thyroiditis
9 75 F Hyperthyroid No TT HCA 0.6 Goiter No Alive - 43
10 47 F Euthyroid Yes TT HCA 1 Goiter No Alive - 30
11 64 F Euthyroid No TT HCC 6 Goiter No Alive - 28
12 26 F Euthyroid Yes Lob HCA 1 Goiter No Alive - 25
13 63 M Euthyroid No TT HCA 1.2 Goiter + Yes Alive - 12
Papillary cancer
14 66 M Euthyroid Yes TT HCC 4 Goiter + Yes Alive - 6
Parathyroid adenoma
15 51 F Hypothyroid Yes TT HCA 2.5 Goiter + Yes Alive - 3
Papillary cancer
+ Thyroiditis
M: males, F: females, FNA: fine needle aspiration, TT: total thyroidectomy, Lob: lobectomy
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complications registered among them were one case
of persistent hypoparathyroidism and one case of
recurrent laryngeal nerve damage. Three patients
with HCC underwent radioiodine treatment after
surgery, on the basis of postoperative serum
thyroglobulin levels and evidence of residual thyroid
tissue at postoperative imaging. Three patients with
HCA underwent radioiodine therapy as they were
affected also by papillary thyroid cancer. No one of
the remaining patients with HCA underwent further
treatment after surgery. There were no recurrences
or progression of the disease among the 13 patients
interviewed.
Discussion
The term “Hurthle Cell” was introduced by Ewing
in 1928 (8). He thought that HCN was made of the
same cells described by Hurthle in the normal
thyroid of dogs in 1894 (9). Although this labelling
is inaccurate because the cells defined by Hurthle are
likely parafollicular (C cells), it remained in the liter-
ature and adopted in the WHO classification of
thyroid neoplasms. Other terms are also used to
describe the same cell type (oxyphilic, oncocytic,
Askanazy) characterized by polygonal and
acidophilic granular cytoplasm with abundant mito-
chondria, ergastoplasm and hypercromatic nuclei.
Thyroid cancer is rare among human malignan-
cies (< 1%) but accounts for over 93% of all cancers
of the endocrine system (10). Worldwide frequency
of thyroid cancer may widely vary because of age,
gender, ethnic, geographic and environmental vari-
ations. HCC assess for approximately 3-7% of
thyroid carcinomas (1-5), even if some authors
report higher incidences, greater than 10% of all
thyroid tumors (11). The mean age of peak inci-
dence of HCC is usually 50-60 years, approximately
10 years greater than the age associated with other
types of differentiated thyroid cancers, being a
disease of adults, whereas papillary and to a lesser
extent follicular cancer occur in younger patients
(12). Evidence of predominance in females about
HCN (male-female ratio reported ranges from 1:3 to
1:5) is present, as for papillary and follicular cancer
of the thyroid (2, 12, 13). Male patients exhibit a
higher frequency of carcinomas (13). In our series
the mean age was 53.8 (range 26 - 76 years), and the
male/female ratio was 1:4.
In the suspect of HCC previous illness or head and
neck irradiation, recent pregnancy, time of onset and
rate of growth of the neck swelling should be
assessed. Most patients with thyroid nodules have
few or no symptoms and no clear relationship exists
between nodule histological type and the reported
symptoms. In our experience 9 HCNs (60%) were
casually discovered. However, some clinical
features may be suggestive of malignancy, as rapid
growth over weeks, hoarseness, dysphagia, dyspnea
and dysphonia, particularly when observed in the
absence of a multinodular goiter. Differentiated
thyroid carcinomas rarely cause airway obstruction,
vocal cord paralysis, or esophageal symptoms as
initial clinical presentation. Hence, the absence of
local symptoms does not rule out malignancy. Most
patients with HCN are euthyroid, but in some cases
signs of thyroid hormonal imbalance may be present.
In our experience 60% of the patients presented
normal thyroid function, 26.7% hyperthyroidism and
13.3% hypothyroidism.
Most commonly the physical examination reveals
a palpable single nodule or multiple neck nodules. If
a single nodule is detected it is important to consider
the location, the size, the consistence and the
mobility in relation to the adjacent deep or superfi-
cial anatomic structures; the firmer the nodule, the
greater the concern for carcinoma. The examination
of the neck includes also the evaluation of eventual
lymphadenopathy: large, multiple, firm, or even
fixed lymph nodes are suggestive of metastatic
carcinoma and may be the first clinical presentation
in some cases.
Ultrasonography actually represents the most
employed diagnostic tool as it is easy to perform,
widely available and without radiation exposure
risks and high costs (14). It represents the most
sensitive method in the survey of thyroid disease,
particularly in detection and description of thyroid
neoplasms and cervical nodal metastases (15), and it
was the only imaging examination used in our study.
Several ultrasonographic findings in the contest of a
thyroid nodule may be associated with a higher like-
lihood of malignancy such as microcalcifications,
hypoechogenicity, irregular margins, predominant
central flow and a shape taller than the width
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measured in the transverse dimension. In spite of its
high sensitivity its specificity is low, especially in
recognizing HCNs.
131I Scintigraphy is traditionally recommended for
nodules greater than 1 cm with indeterminate
cytology, even though it is not a routine test for the
investigation of thyroid nodules. When a cold or hot
nodule is detected, the possibility of malignancy
amounts for 38.5% and 2.5%, respectively. Uptake in
the nodule indicates its benign nature and spares
patients from surgery due to suspicion of malignancy
(14). However, scintigraphy does not always permit
an unequivocal interpretation. Positron emission
tomography (PET) with different radionuclides have
similar limitations. The major role of nuclear medi-
cine tests is the detection and treatment with radioac-
tive iodine for residual malignant thyroid tissue and
metastatic disease in patients with differentiated
thyroid carcinoma after total thyroidectomy (4).
Usually both CT and magnetic resonance imaging
(MRI) have a limited role in the initial investigation
of a patient presenting with a thyroid nodule. In
invasive thyroid malignancy, cross-sectional
imaging helps to evaluate extra-thyroid spread of
tumor to adjacent anatomical structures and provides
evidence of regional or distant metastases in order to
decide the best therapeutic strategy (15).
FNAB is safe, cheap, minimally invasive, and
highly accurate in the diagnosis of thyroid nodules.
It has been shown to have a diagnostic sensitivity of
89% to 98% and a specificity of 92% (16) in
detecting thyroid cancer with overall false negative
and false positive rates ranging from 0.5% to 11.8%
and from 0% to 7.1% respectively (15). The sensi-
tivity and specificity in the identification of HCNs is
correspondingly 97% and 100%, but it is substan-
tially incapable of distinguish HCC from HCA.
Cytological findings of a Hurthle cell lesion with a
high degree of atypia are highly suspicious for
malignancy; furthermore HCAs have a broader
range of cytological features than carcinomas and
may present with an abundant colloid matrix. It is
important to consider that Hurthle cells may also be
present in a wide range of benign conditions
including hyperplasic nodules in Hashimoto
thyroiditis and adenomatous - multinodular goiters
with Hurthle cell metaplasia. Differential diagnosis
is of primary importance in these cases.
A wide set of criteria has been proposed for the
cytological diagnosis of HCN including cytoarchi-
tecture, monomorphism, macronucleoli and among
all vascular or capsular invasion (17). These last
features are certainly better examined in a surgical
specimen. For this reason some authors use intraop-
erative frozen-section (FS) biopsy to confirm the
FNAB findings and to guide the extent of thyroidec-
tomy in order to avoid a subsequent completion
thyroidectomy (18). However, FS evaluation may
miss vascular or capsular invasion because of the
limited number of sections and the presence of arte-
facts. In these cases, final diagnosis is deferred to
examination of the entire capsule and a completion
procedure may be required. Some authors have not
found any difference in sensitivity and specificity
between FS and FNAB (19). Such speculations
suggest that FNAB is useful in the preoperative eval-
uation of patients with nodular thyroid disease, but
only histological examination of the entire lesion
surgically excised is capable to detect the presence
of capsular or vascular invasion.
Following the diagnostic uncertainties, it is not
easy to asses the appropriate treatment of HCNs on
the basis of preoperative findings. Some authors
recommend total or near-total thyroidectomy (TT) in
all cases, while others suggest a less aggressive
approach as lobectomy or isthmusectomy followed
by completion thyroidectomy if necessary. TT is
also preferred because oxyphilic neoplasms often are
found in the context of multinodular goiter or
nodular Hashimoto’s thyroiditis (20), as it happened
in 73% of our patients. It is also recommended if the
primary thyroid carcinoma is larger than 1 cm, when
contralateral thyroid nodules and regional or distant
metastases are present. TT is also indicated when the
patient has a head and neck radiation history or a
first-degree family history of differentiate thyroid
carcinoma. Some authors consider age greater than
45 years a criterion to choose near-total or TT even
for small tumors because of the higher recurrence
rate in this age group (21). Lobectomy should be
considered in low-risk patients with minimally inva-
sive tumors, while isthmusectomy is not recom-
mended. Compartment-oriented lymph node dissec-
tion should be performed in cases of clinically
and/or intraoperatively evidenced lymph node
involvement. Ipsilateral lymph node metastatic
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lesions occur in about 25% of patients with HCC
(22). With less extensive resection the recurrence
rate in the contralateral lobe is approximately 7%,
and 50% of patients with recurrent differentiate
thyroid carcinoma will eventually die from this
disease (23). No one of our patients had evidence of
cervical lymphadenopathy, preoperatively or intra-
operatively.
The surgical risks of two-stage thyroidectomy
(lobectomy followed by completion thyroidectomy)
are similar to those of TT and generally consist in
recurrent laryngeal nerve damage and permanent
hypoparathyroidism. These complications may be
reduced in experienced hands, but unilateral resec-
tion is clearly associated with fewer complications.
Controversy exists as regards the use of 131I as less
than 10% of HCCs take up the radionuclide and does
not appear to improve outcomes in patients with
HCC. After a partial or subtotal thyroidectomy,
radioiodine can be employed for thyroid residue
ablation and to detect recurrence. External irradia-
tion should be selectively used in cases of unre-
sectable tumors especially in absence of 131I uptake
and for isolated bone metastases after surgical resec-
tion (24).
The identification of prognostic factors able to
predict the biological and clinical behaviour of HCN
may influence the appropriate choice of surgical or
adjuvant therapy in order to reduce over treatment. It
may also be useful in selecting patients who need a
careful follow-up after primary therapy. An associa-
tion has been observed between older age and HCC.
Lopez-Penabad et al. and Yi Wei Zhang et al. found
a clear difference in age in patients with HCA and
HCC (3, 25). Our results confirm this trend: the
mean age in patients with HCC and HCA was
respectively 62 and 51 years.
As regards the correlation between tumor size and
malignancy risk, no clear evidence exists. Some
studies suggest that HCC has a tendency to present a
larger size than HCA at the time of diagnosis (2). In
the study of Chen et al.HCC exhibited a mean tumor
size at presentation of 4.0 cm, whereas HCA had a
mean tumor size of 2.4 cm (26), while Sippel et al.
demonstrated a proportional increase of the risk for
malignancy when tumor size raises (27). Neverthe-
less, Chen et al. found a 23% risk of malignancy in
lesions 1-4 cm (26) and Giorgadze et al. a 45% risk
in lesions smaller than 2 cm (28). Even in our study
the nodule size was associated with a higher risk of
malignancy: HCC had a mean tumor diameter of 3.8
cm and HCA of 1.6 cm. Considering that adenomas
are often larger than 2 cm and sometimes overpass 5
cm in diameter, the size of the lesion alone cannot be
used as a criterion of malignancy (13). Other
evidences suggest that the size of HCCs correlates
with the aggressiveness of the tumor (24,29) but no
definitive conclusions exist on the topic. Local inva-
sion and extraglandular expansion adversely influ-
ence survival as well as lymph node involvement
and distant metastases. In particular the occurrence
of distant metastases (especially bone and lung
metastases) is considered the factor with the worst
impact on prognosis (24).
One of the most debated issues regarding HCNs is
to predict their clinical behaviour on the basis of
pathological criteria. Historical studies demonstrate
that there is not always an exact correlation between
histological features and oncologic nature of such
lesions (30,31). Thompson et al. report 11 deaths
among 25 patients with HCN and malignant behav-
iour in 3 out of 4 patients with HCA, concluding that
all HCNs must be considered as malignant, irrespec-
tive of size (32). This experience seems exceptional,
considering that most recent studies exclude any
malignant behaviour in benign Hurthle cell lesions.
Bondeson et al. reported 34 patients with HCA
without evidence of clinically malignant evolution
(33). Similarly in our experience no one of the
patients with HCA presented malignant course, even
after several years of follow-up in some cases.
However many authors believe that HCNs are to
consider always malignant but with a different
progress capacity.
Conclusions
HCNs are rare neoplasms of the thyroid gland,
amounting in our experience for the 2.3% of the
overall surgical operations for thyroid disease. Clin-
ical manifestations are similar to those of other
differentiated thyroid neoplasms and the best diag-
nostic tools in our practice was ultrasound and
FNAB. Our data suggest that HCAs have no malig-
nant potential as some authors reported in the past,
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but surgical resection is necessary in order to obtain
a precise evaluation of eventual infiltrative events.
Surgical resection is the treatment of choice for the
treatment of HCNs and total thyroidectomy repre-
sents in our opinion the best surgical option, while
larger interventions have to be considered in cases of
advanced disease and lobectomy in low-risk patients
with minimally invasive tumors.
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